Skip to main content

Table 1 Patients’ characteristics

From: Axillary ultrasound for predicting response to neoadjuvant treatment in breast cancer patients—a single institution experience

 

N = 244

Age (median, range)

48 (27–78)

Subtype

Luminal

124 (50.8%)

Her-2 + 

78 (32.0%)

TN

42 (17.2%)

Histology

Invasive ductal carcinoma

234 (95.9%)

Invasive lobular carcinoma

7 (2.9%)

Other

3 (1.2%)

 Tumor size at presentationa

31 (4–100)

 Tumor size after NASTa

10 (0–85)

  1. Her-2 human epidermal growth factor receptor 2, NAST neoadjuvant systemic treatment, TN triple negative
  2. aMedian tumor size on ultrasound or magnetic resonance imaging in milimeters with range